// startup autopsy

BiotechMX

Mexico biotech with 36-month COFEPRIS approval while IMSS required 5-year track record and BIRMEX had exclusive mandate for vaccine production

regulationSlow Death

Years-long decline before final shutdown · Fatal mistake: Mexico biotech: COFEPRIS (health regulator) clinical trial approval took 36+ months for novel biologics. IMSS (45M insured) procurement required 5-year local track record. ISSSTE had separate procurement process. BIRMEX (government biologics manufacturer) had exclusive vaccine production mandate. PISA and Liomont (Mexican pharma) had COFEPRIS relationships from 30+ years. Independent biotech had 36-month regulatory path before any revenue.

Founded	2018
Closed	2023
Country	Mexico
Sector	Biotech

// the model, blind

Evaluating only BiotechMX’s profile at its peak — without knowing the outcome — the model ranked Regulation as the #1 likely cause. That’s exactly how it died.

Key Events Timeline

2018

FOUNDING

2021

CRISIS

2023

SHUTDOWN

Full Analysis

Free · no account needed

Documented cause

BiotechMX built biologic. COFEPRIS 36 months. IMSS 5-year track record. BIRMEX exclusive mandate. PISA/Liomont 30+ year relationships. Needed 60 months before revenue. Dissolved.

Lesson

“Mexico biotech must use COFEPRIS Fast Track for drugs targeting neglected tropical diseases (dengue, Chagas, leishmaniasis endemic in Mexico) — Fast Track reduces approval to 18 months and opens IMSS/ISSSTE procurement without track record.”

Failure anatomy

Collapse type

Slow Death

🐌 LOW

Hype cycle

None

Moat type

Technology

Fatal mistake

Mexico biotech: COFEPRIS (health regulator) clinical trial approval took 36+ months for novel biologics. IMSS (45M insured) procurement required 5-year local track record. ISSSTE had separate procurement process. BIRMEX (government biologics manufacturer) had exclusive vaccine production mandate. PISA and Liomont (Mexican pharma) had COFEPRIS relationships from 30+ years. Independent biotech had 36-month regulatory path before any revenue.